Previous Article | Next Article ![]()
Journal of Virology, March 2001, p. 2194-2203, Vol. 75, No. 5
Department of Pediatrics, UCLA School of
Medicine, Los Angeles, California
Received 27 June 2000/Accepted 21 November 2000
Previous studies have provided conflicting data on the presence of
selective pressures in the transmission of a homogeneous maternal viral
subpopulation to the infant. Therefore, the purpose of this study was
to definitively characterize the human immunodeficiency virus type 1 (HIV-1) quasispecies transmitted in utero and intrapartum. HIV-1
envelope gene diversity from peripheral blood mononuclear cells and
plasma was measured during gestation and at delivery in mothers who did
and did not transmit HIV perinatally by using a DNA heteroduplex
mobility assay. Children were defined as infected in utero or
intrapartum based on the timing of the first detection of HIV.
Untreated transmitting mothers (n = 19) had
significantly lower HIV-1 quasispecies diversity at delivery than
untreated nontransmittting mothers (n = 18) (median
Shannon entropy, 0.711 [0.642 to 0.816] versus 0.853 [0.762 to
0.925], P = 0.005). Eight mothers transmitted a
single major env variant to their infants in utero, and
one mother transmitted a single major env variant intrapartum. Four mothers transmitted multiple HIV-1 env
variants to their infants in utero, and two mothers transmitted
multiple env variants intrapartum. The remaining six
intrapartum- and two in utero-infected infants had a homogeneous HIV-1
env quasispecies which did not comigrate with their
mothers' bands at their first positive time point. In conclusion, in
utero transmitters were more likely to transmit single or multiple
major maternal viral variants. In contrast, intrapartum transmitters
were more likely to transmit minor HIV-1 variants. These data indicate
that different selective pressures, depending on the timing of
transmission, may be involved in determining the pattern of maternal
HIV-1 variant transmission.
Worldwide, human immunodeficiency
virus type 1 (HIV-1) infection is spreading rapidly in women of
childbearing age (15). In the United States alone, more
than 100,000 women are currently infected with HIV-1 (31)
and 2,000 infants are born to HIV-1-positive mothers each year
(33). The epidemic of HIV-1 infection in women of
childbearing age represents a serious threat to children, because more
than 95% of infected children acquire HIV-1 from their mothers. Zidovudine (ZDV) treatment of infected mothers during gestation and at delivery and of their infants during the first 6 weeks of life
has been shown to decrease the risk of perinatal transmission in
treatment-naive, non-breast-feeding women by more than 70% (3,
8, 36). However, several factors, including advanced maternal
disease status, the spread of antiretrovirus-resistant virus,
noncompliance with therapy, and lack of an alternative to
breast-feeding in certain populations, contribute to the continued spread of HIV-1 infection from mothers to their infants.
One major area of controversy in the field of pediatric HIV-1 infection
has been whether selective transmission of a specific, homogeneous
maternal viral population to the infant occurs in utero or intrapartum.
In 1992, Wolinsky et al. published data indicating that the transmitted
strain was a minor variant of the maternal viral pool
(40). He and others have used such data to suggest the
presence of selective pressure in determining which HIV-1 variants are
transmitted (1). Data from other studies however, have
shown a more random pattern of transmission of multiple and/or major
maternal HIV-1 variants (22, 25). The lack of consensus
among these studies may be due to the facts that each study compared
only a few mother-infant pairs and the results were not correlated with
the timing of transmission. Therefore, questions remain regarding the
selective transmission of maternal HIV-1 variants in both in utero and
intrapartum perinatal HIV-1 infection.
The constant evolution of HIV-1 in vivo results in the presence of
numerous genetic strains referred to as quasispecies. HIV-1 variants arise in vivo due to the high mutation rate of reverse transcriptase and a short generation time and in response to diverse selective pressures (30, 37). The level of HIV-1
env gene diversity in vivo has been inversely correlated
with the rate of disease progression in infected adults and children
and provides an indication of the presence of selective pressures
exerted by the host immune response (16, 39). The pressure
exerted by maternal autologous neutralizing antibody (20)
and cell-mediated immunity (28, 38) could result in the
selective transmission of HIV-1 escape variants to the infant. However,
the lack of a strong maternal neutralizing antibody response may also
be correlated with increased viral load and, therefore, with the risk
of random transmission (14).
In order to determine if selective pressure is indeed involved in in
utero and/or intrapartum perinatal HIV-1 transmission, we conducted a
genetic analysis of maternal and perinatally transmitted HIV-1 strains.
Heteroduplex mobility analysis (HMA) (12) was used to
determine the degree of HIV-1 envelope gene diversity in
HIV-1-infected, transmitting and nontransmitting mothers at delivery.
HIV-1 env region sequences in infected mother-infant pairs
were compared by HMA to determine the degree of genetic relatedness
between the maternal viral quasispecies and perinatally transmitted
variants. Our results support the presence of selective pressure in
perinatal HIV-1 transmission but suggest, however, that different
pressures may be involved in determining which maternal env
variants are transmitted in utero and intrapartum.
(This work was presented in part at the Seventh Conference on
Retroviruses and Opportunistic Infections, San Francisco, California, January 2000.)
Patient information and samples. (i) Mothers.
The 59 seropositive mothers studied were monitored as part of a prospective
study of maternal-fetal HIV-1 transmission conducted by the Los Angeles
Pediatric AIDS Consortium between May 1989 and August 1995. The
mothers were chosen as study participants based on sample availability,
including at least one pre-term (mean, 3 ± 2) and one
time-of-delivery sample. Mothers were also chosen based on the
availability of samples from their infants from within 48 h of
delivery and sufficient clinical follow-up of both the mothers and
their infants. Of a total of 116 HIV-1-infected mother-infant pairs
monitored throughout the study period, 57 (13 transmitters and 44 nontransmitters) were excluded based on a lack of infant samples within
the first 48 h following delivery (n = 23), lack
of appropriate maternal samples (n = 20), and/or lack
of sufficient clinical follow-up (n = 14). Samples were
collected from patients with informed consent under the approval of the institutional review boards at each site participating in the study.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.5.2194-2203.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Perinatal Transmission of Major, Minor, and
Multiple Maternal Human Immunodeficiency Virus Type 1 Variants In
Utero and Intrapartum
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
(ii) Infected infants. Samples were collected within 48 h of birth and at 2, 4, 6, 8, 10, and 12 weeks of age from 23 infants defined as infected following at least two positive HIV-1 cocultures from peripheral blood at two separate time points and confirmation of seropositive status beyond 15 months of age. According to the current working definition, infected infants with positive HIV-1 cocultures and/or PCRs (coculture/PCRs) within 48 h following birth were defined as infected in utero, whereas those with negative coculture/PCRs within 48 h of birth and with subsequent positive coculture/PCRs were defined as infected intrapartum (6). Two infected infants born to ZDV-treated mothers received ZDV during the 12 weeks of follow-up for this study. No infants were breast-fed.
Methods. (i) Sample preparation. Ficoll-Hypaque density gradient centrifugation was used to prepare peripheral blood mononuclear cells (PBMCs) from heparinized (HIV-1 coculture) or EDTA (PCR and flow cytometry)-treated samples. Mononuclear cells were washed with normal saline twice and enumerated, and cells not used immediately were stored under liquid nitrogen. PBMC DNA and viral RNA in plasma were prepared from maternal and infant EDTA-treated samples by using QIAmp DNA and QIAmp viral RNA kits (Qiagen, Inc., Valencia, Calif.).
(ii) Quantitative PCR. Quantitative HIV-1 RNA PCR was performed on maternal plasma samples by using the AMPLICOR HIV-1 MONITOR assay according to the manufacturer's instructions (Roche Molecular Systems, Somerville, N.J.). Samples in which HIV-1 RNA was not detected were assigned a value of 50 RNA copies/ml in the statistical analysis. Quantitation of HIV-1 DNA in PBMCs was performed by PCR, using previously published methods (13). Samples with copy numbers of less than 10 were assigned a value of 5 HIV-1 DNA copies/µg of PBMC DNA in the statistical analysis.
(iii) HIV-1 culture. Quantitative PBMC cocultures were performed in 24-well plates according to the NIH/NIAID Clinical Trials Group consensus protocol (2, 13). Negative HIV-1 cocultures were assigned a value of 0.1 HIV-1-infected PBMC/106 cells in the statistical analysis. Quantitative plasma cultures were performed on fresh (n = 49) and frozen (n = 10) plasma samples according to the NIH/NIAID Clinical Trials Group consensus protocol (2, 13). Negative plasma cultures were assigned a value of 1 tissue culture infective dose (TCID)/ml of plasma in the statistical analysis.
(iv) Flow cytometry. Flow cytometric analysis of PBMCs was performed as previously published (18).
(v) HMA.
Reverse transcription of HIV-1 RNA purified from
EDTA-treated plasma was carried out by using random hexamers from the
GeneAmp RNA PCR kit according to the manufacturer's instructions
(Perkin-Elmer Cetus, Emeryville, Calif.). In order to optimize the
sensitivity of viral variant detection and to ensure proper sampling,
the starting HIV-1 RNA and DNA copy numbers were determined by the methods listed above for each specimen used in the HMA
(11). First-round nested PCRs consisted of
1 µg of
PBMC DNA (starting copy number of 30 to 40) or cDNA derived from
200
µl of plasma (starting copy number of 500 to 1,000), 1.7 mM
MgCl2, 0.2 µM concentrations of each primer in
50 µM KCl, 10 mM Tris (pH 8.3), 200 µM concentrations of each
nucleoside triphosphate, and 2.5 U of Taq DNA polymerase (Perkin-Elmer Cetus) in a final volume of 50 µl. Amplifications were
carried out in a DNA Thermal Cycler 9600 (Perkin-Elmer Cetus) for 35 cycles consisting of 10 s at 95°C, 10 s at 62°C, and
30 s at 72°C. The first-round PCR primer pair was RedE1 (5'
ATTATGGGGTACCTGTGTGG 3', HXB2R position 5886) and RedE2 (5'
CTGCACCACTCTTCTCTTAG 3', HXB2R position 7288) (32).
For patients with fewer than 20 copies of HIV-1 DNA/µg of PBMC DNA,
multiple first-round PCR amplifications were performed and the
independent runs were combined. The first-round PCR products were
concentrated in QIAquick PCR columns (Qiagen), and the entire purified
PCR product was used in the second-round PCR amplification in order to
prevent the loss of any sequence diversity. Second-round PCRs were
carried out as described above, using primer pair RedE3 (5'
TAGGCCAGTAGTATCAACTC 3', HXB2R position 6523) and RedE4 (5'
GACTTCTCCAATTGTCCCTC 3', HXB2R position 7195), generating a final
PCR product approximately 690 bp in length.
(vi) Data analysis. HMA gel photographs were scanned by using Adobe Photoshop (Adobe Inc., San Jose, Calif.) and stored as binary TIFF files. Gel lane scans were performed on a PowerMac computer, using the public domain NIH Image program (developed at the National Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nih-image). Lane scans of equal length (144 pixels) were recorded from immediately below the single-stranded DNA to immediately below the homoduplex. The quasispecies diversity, or sequence heterogeneity, for each sample was estimated by calculating the normalized Shannon entropy using the NIH Image Entropy tool (10). The quasispecies sequence divergence, or percent base pair mismatch in reannealed strands, for each sample was estimated by calculating the median mobility shift (MMS) with the NIH Image Distance tool (10).
(vii) Statistics.
Descriptive statistics are provided as
median (25th and 75th percentile). Correlations between
individual variables were determined using a Spearman rank correlation
coefficient (rho). Maternal, virologic, and immunologic variables
between groups were compared using the Mann-Whitney U,
2, and Fisher's exact tests. P
values of less than or equal to 0.05 were considered significant.
| |
RESULTS |
|---|
|
|
|---|
Patient characteristics. Samples were available for analysis from 59 HIV-1-infected mothers and their infants. The majority of the infected women enrolled in our study were asymptomatic (85% belonged to CDC class A), with a median (25th and 75th percentile) CD4+ T-cell count at delivery of 500 (322 and 687)/mm3. Fourteen mothers transmitted HIV-1 to their infants in utero based on positive HIV-1 coculture and PCR within 48 h of delivery. Nine mothers transmitted HIV-1 to their infants intrapartum based on negative HIV-1 coculture and PCR within 48 h of delivery with subsequent follow-up positives (2 to 6 weeks after delivery). The thirty-six infants born to the nontransmitters in our study were defined as uninfected based on seroreversion by enzyme-linked immunosorbent assay or Western blotting.
HIV-1 quasispecies diversity in mothers at delivery.
The
degree of differentiation of the maternal HIV-1 quasispecies was
assessed by HMA performed on cell-associated and cell-free virus from
transmitting and nontransmitting mothers at delivery. An approximately
690-bp nested PCR product encompassing the V3 to V5 regions of the
HIV-1 gp120 gene was amplified from each mother and used to form
heteroduplexes. Figure 1 shows
representative patterns of HIV-1 homo- or heteroduplex migration
observed in 16 HIV-1-infected transmitting and nontransmitting mothers
at delivery. The majority of mothers studied showed the presence of
multiple, slowly migrating heteroduplexes formed from amplified PBMC
proviral DNA at delivery (83%; Fig. 1). Ten mothers (5 transmitters and 5 nontransmitters) with low CD4 counts (median,
190/mm3) had very low levels of proviral DNA
env gene diversity as exhibited by the presence of a single,
rapidly migrating homoduplex. Of note, all five nontransmitters with a
single homoduplex received ZDV during gestation. As seen in Fig. 1,
plasma-derived viral RNA showed a somewhat lower degree of
differentiation than the proviral DNA, with 75% of infected mothers
exhibiting slowly migrating cDNA heteroduplexes at delivery.
|
0.40, P = 0.004). HIV-1 RNA quasispecies entropy among
mothers at delivery also correlated with maternal
CD4+ cell count (rho = 0.45, P = 0.003) and was inversely correlated with maternal
plasma HIV-1 RNA levels (rho =
0.40, P = 0.004). The HIV-1 proviral DNA and plasma RNA MMS correlated well with maternal
CD4+ cell count (DNA MMS/CD4, rho = 0.426, P = 0.003; RNA MMS/CD4, rho = 0.409, P = 0.004) and both showed an inverse correlation with
HIV-1 RNA levels in maternal plasma at delivery (DNA MMS/RNA, rho =
0.401, P = 0.005; RNA MMS/RNA, rho =
0.349,
P = 0.010).
Figure 2A shows the normalized Shannon
entropy for PBMC-derived proviral DNA V3-V5 env region
heteroduplexes from each mother in our study at delivery. While the
median HIV-1 DNA quasispecies entropy at delivery was lower in
transmitters compared to all 36 nontransmitters studied, the observed
trend did not reach statistical significance due to the large overlap
between groups (Fig. 2A; P = 0.053). The median rate of
HIV-1 RNA quasispecies entropy in plasma was lower than the rate of
proviral DNA quasispecies entropy among both transmitters and
nontransmitters, and the difference between these two groups was not
significant (E = 0.595 [0.543 and 0.740] versus 0.692 [0.567 and 0.778], P= 0.283).
|
|
HIV-1 diversity and the timing of transmission.
The results of
our study also showed that women who transmitted HIV-1 infection to
their infants in utero had significantly lower rates of HIV-1 proviral
DNA and viral RNA env gene diversity and divergence in
plasma at delivery as well as significantly lower CD4 counts than women
who transmitted the virus intrapartum (Table
2). At delivery, mothers who transmitted
HIV-1 to their infants in utero were significantly less likely to have
multiple distinct HIV-1 proviral DNA env strains as
exhibited by the presence of a single rapidly migrating homoduplex than
mothers who transmitted intrapartum (5 of 14 versus 0 of 9, P = 0.043; Fig. 1B).
|
Pattern of maternal viral quasispecies transmission.
In order
to characterize the pattern of maternal HIV-1 quasispecies transmission
in utero and intrapartum, PBMCs and plasma-derived HIV-1 env
gene PCR fragments derived from the 23 transmitters in our study were
analyzed alongside those of their infants. Figures 3 and 4 show representative examples of
the maternal-infant HMA comparisons
performed in our study. Seventeen mothers transmitted a single HIV-1
env variant to their infants as evidenced by a single infant
HIV-1 env homoduplex generated from PBMCs and plasma at
their first positive time point (Fig. 3A and C and 4A and C). The
remaining six mothers transmitted multiple distinct HIV-1 env strains to their infants as evidenced by the presence of
multiple slowly migrating heteroduplexes derived from infant PBMCs
(n = 6 of 6) and plasma (n = 2 of 6) at
their first positive time point (Fig. 3B and 4B).
|
|
|
Viral env gene evolution over time. HIV-1-infected transmitting mothers and their infants were monitored over time in order to determine the pattern of viral env gene evolution during gestation and shortly after birth. As shown in Fig. 3 and 4, little to no HIV-1 env gene evolution was demonstrated by HMA throughout gestation in the majority of transmitting mothers. Nine transmitters showed noticeable but slight changes in HIV-1 env gene HMA banding patterns over time. One in utero transmitter had a decrease in the total number of HMA bands, indicating a decrease in the number of distinct viral env gene strains present. Eight transmitters (two in utero and six intrapartum) showed an increase in viral env gene divergence throughout the gestation period; however, these changes were small (Fig. 3C and 4C). Based on these nine mothers, both in utero- and intrapartum-transmitted strains matched most closely maternal strains at delivery. However, multiple closely spaced samples from the third trimester were not available to further elucidate the timing of transmission.
In contrast to their mothers, several infected infants showed dramatic changes in both HIV-1 env gene diversity and divergence during the first 12 weeks following delivery. While 8 HIV-1-infected infants monitored from birth through 12 weeks showed constant levels of HIV-1 env gene diversity and divergence (Fig. 3A), 5 infants showed decreases (Fig. 3B and 4B), and 10 showed increases (Fig. 3C, 4A, and 4C). These results indicate that rapid evolution of HIV-1 env gene sequences can occur early in perinatal infection.Comparison of HIV-1 populations in plasma and PBMCs. To assess the degree of relatedness between cell-associated and cell-free viral populations, env gene PCR products derived from PBMCs and plasma were combined and analyzed by HMA. In the majority of transmitting mothers (91.3%), the PBMC- and plasma-derived env PCR products comigrated without the formation of novel heteroduplexes on the HMA gels, indicating a high degree of genetic relatedness (data not shown). In 21 of 23 infected infants, the plasma- and PBMC-derived viral env gene populations also showed a high degree of genetic relatedness as indicated by the formation of homoduplexes with or without a small amount of smearing (data not shown).
Two transmitting mothers (one in utero and one intrapartum) in our study had distinct viral populations in their PBMCs and plasma at delivery as evidenced by the formation of new heteroduplexes on HMA gels (Fig. 5). Both of the infants born to these women also possessed distinct HIV-1 env strains in their PBMCs and plasma at their first positive time point (Fig. 5). Cross-mixing of maternal and infant PBMC- and plasma-derived env gene PCR products followed by HMA analysis indicated that the cell-associated virus present in these two infected infants at their first positive time point (one at birth and one at 2 weeks of age) was most closely related to the virus in their mothers' PBMCs at delivery. Likewise, the plasma-derived viral env gene PCR products from these two infected infants were most closely related to the viral env gene products derived from maternal plasma at delivery, suggesting that both cell-associated and cell-free transmission of HIV-1 can occur in utero and intrapartum (Fig. 5).
|
| |
DISCUSSION |
|---|
|
|
|---|
Virologic and immunologic factors associated with an increased risk of perinatal transmission include high maternal virus load at delivery, advanced maternal disease status, and low maternal CD4+ cell count (7, 14, 17, 34, 35). In the present study, HMAs of maternal PBMCs and viral PCR products in plasma indicated that HIV-1 env gene diversity at delivery is also associated with the risk of perinatal transmission. Viral env diversity is generated in the presence of host immune pressures, necessitating genetic evolution in order to ensure viral escape. Zhang et al., in a study of adults with primary HIV-1 infection, found no HIV-1 env gene diversity prior to seroconversion (41). Previous studies have also indicated a correlation between host immune control of virus replication, the development of HIV-1 env gene diversity, and a lower rate of disease progression (10, 11, 16, 39). The results of our study provide evidence for the importance of maternal immune control of virus replication, as evidenced by HIV-1 RNA levels and HIV-1 env gene diversity, in prevention of perinatal HIV-1 transmission in utero.
While mothers who transmitted HIV-1 to their infants in utero exhibited lower levels of viral env gene diversity, intrapartum transmitters had diversity levels similar to those of ZDV-untreated nontransmitting mothers. The higher CD4 counts and high levels of env gene diversity observed in these mothers indicate that intrapartum transmission can occur even in the presence of an active maternal immune response. Possible factors that preclude in utero transmission, including the presence of maternal anti-HIV-1 antibodies and cell-mediated immunity, may be overwhelmed by obstetrical events during delivery and may lead to intrapartum transmission (21, 23).
The majority of ZDV-treated women in our study were enrolled prior to the publication of ACTG 076 (8); thus, treatment of these mothers was initiated prior to or during gestation based on maternal clinical parameters. ZDV treatment during gestation decreased HIV-1 RNA copy numbers in maternal plasma to levels similar to those seen in untreated nontransmitters. However, a concomitant significant increase in maternal CD4 count and HIV-1 env gene diversity was not observed. These data indicate that low maternal HIV-1 env gene diversity is not in and of itself sufficient to promote perinatal HIV-1 transmission. Rather, our results emphasize the importance of maintaining low maternal viral loads via either immunologic and/or antiretroviral control strategies in order to minimize the risk of perinatal transmission.
While 78% of transmitting mothers possessed multiple distinct HIV-1 env strains during gestation and at delivery, 74% of their infants were infected with a single env variant at their first positive time point. Even among infants infected with multiple HIV-1 viral strains, the V3-V5 region analyzed by HMA was found to be more homogeneous than that of their mothers at delivery. These data provide strong evidence for the presence of selective pressures, resulting in the transmission of a limited number of HIV-1 quasispecies via both the in utero and intrapartum routes of perinatal transmission. In addition, the difference observed in the pattern of maternal HIV-1 quasispecies transmission according to the timing of transmission indicates that different selective pressures may be involved in determining which variants are transmitted in utero and intrapartum.
Possible selective pressures influencing perinatal HIV-1 transmission include maternal viral phenotype, tropism, coreceptor usage, maternal neutralizing antibody, and/or other immune pressures (19, 24, 27, 38). In the present study, low maternal CD4 counts and low rates of HIV-1 env gene diversity were observed primarily in mothers transmitting major env variants to their infants in utero. Previously, we reported that in utero HIV-1 transmission is also associated with a weak maternal autologous neutralizing antibody response (5). These results, in combination with those of the present study, suggest that poor maternal immunologic control of viral replication can lead to perinatal transmission of major HIV-1 variants.
In contrast, the intrapartum transmitters studied here had lower HIV-1 RNA levels and more HIV-1 env gene diversity, suggesting the presence of a more active antiviral immune response, which may have led to transmission of minor escape variants to the infant. An alternative explanation is that minor variants arise due to outgrowth of a rapidly evolving population within the infant. In fact, among infants infected both in utero and intrapartum with minor maternal HIV-1 variants at their first positive time point, a rapid rate of viral env gene evolution was observed throughout the 12-week follow-up period. Further studies are needed to determine if the rapid rate of HIV-1 env gene evolution observed in these infants is due to the presence of passively transferred maternal antibodies and/or to an active infant antiviral immune response.
We attempted to use HMA analysis to determine the time of in utero versus intrapartum transmission as early or late in gestation. Unfortunately, little to no significant maternal HIV-1 env gene evolution was observed during gestation among most of the transmitters studied. This may be due to the additional amount of immune suppression that occurs during pregnancy or to the presence of a weak antiviral immune response as indicated by low rates of HIV-1 env diversity in the majority of transmitting mothers. While the divergence among HIV-1 env strains increased during gestation in several transmitters, evidence for the generation of novel env strains was extremely limited and heteroduplex patterns indicated that early viral strains persisted throughout pregnancy. Thus, while more frequent maternal sampling might allow further clarification, the small amount of virus evolution observed during pregnancy and the persistence of early strains indicate that it may not be possible to determine exactly the timing of perinatal transmission by using molecular methods (9).
Similar difficulties were encountered in our attempt to identify the source of viral inoculum transmitted to the infant as from maternal PBMCs or plasma. HMA comparisons of PBMC and plasma viral populations in transmitting mothers and their infants indicated that viral env strains in plasma existed as major or minor subpopulations of strains present in PBMCs. Some evidence was found to support the genetic relationships between maternal and infant PBMC viral strains and maternal and infant viral strains in plasma. However, it is not clear if this linkage is due to transmission via both PBMCs and plasma or if transmission of multiple PBMC strains followed by seeding of plasma with replication-competent strains occurred.
Among the six intrapartum-transmitting mother-infant pairs in which infection with a minor maternal HIV-1 strain was found to have occurred, neither maternal PBMCs nor maternal env strains in plasma formed a close match with infant env strains. Previous studies have indicated that mucosal membranes, including the cervix, harbor HIV-1 envelope variants distinct from those found in PBMCs and plasma (26, 29). Therefore, it may be that maternal cervical secretions provided the source of HIV-1 inoculum in these cases; however, we did not have appropriate samples available to test this hypothesis. However, the lack of a good match between the intrapartum-transmitted mother and infant viral strains may also have been due to outgrowth of virus capable of escaping passively transferred antibody and/or with a greater replication potential.
Perinatal HIV-1 transmission is a complex multifactorial process that remains poorly understood. We conducted the first published prospective study of HIV-1 quasispecies transmission in mother-infant pairs with a known definition of the timing of transmission. In contrast to those of several previous reports (1, 25, 40), our data suggest the involvement of multiple mechanisms in perinatal HIV-1 transmission (4) which may differ by the timing of transmission. In addition, the results of the present study indicate that transmission of major, minor, and multiple maternal HIV-1 strains can occur both in utero and intrapartum. Evidence was also found to support the potential importance of different selective pressures during in utero and intrapartum transmission. This paper extends our understanding of factors influencing perinatal transmission both in utero and intrapartum; however, further study of the mechanisms influencing selective transmission of the maternal HIV-1 quasispecies is clearly indicated.
| |
ACKNOWLEDGMENTS |
|---|
This research was supported in part by grants HD30629 and HD26621 from the National Institute of Child Health and Human Development; by ACTG AI27550, AI30629, and AI32440 from the National Institute of Allergy and Infectious Diseases; by Universitywide AIDS Research Program grants K97-LA-101 and R91-LA-152; by Clinical Research Center grant RR-00-865; and by the Pediatric AIDS Foundation, Santa Monica, Calif.
We thank Margaret Keller, Audra Deveikis, and E. Richard Stiehm for providing the maternal and infant samples and for clinical follow-up.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Pediatrics, UCLA Medical Center, 10833 Le Conte Ave., Los Angeles, CA 90095. Phone: (310) 825-9161. Fax: (310) 206-4764. E-mail: ybryson{at}mednet.ucla.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Ahmad, N., B. M. Baroudy, R. C. Baker, and C. Chappey. 1995. Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission. J. Virol. 69:1001-1012[Abstract]. |
| 2. | AIDS Clinical Trials Group Virology Technical Advisory Committee. 1994. ACTG virology manual for HIV laboratories. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. |
| 3. |
Boyer, P. J.,
M. Dillon,
M. Navaie,
A. Deveikis,
M. Keller,
S. O'Rourke, and Y. J. Bryson.
1994.
Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery.
JAMA
271:1925-1930 |
| 4. | Briant, L., C. M. Wade, J. Puel, A. J. Brown, and M. Guyader. 1995. Analysis of envelope sequence variants suggests multiple mechanisms of mother-to-child transmission of human immunodeficiency virus type 1. J. Virol. 69:3778-3788[Abstract]. |
| 5. | Bryson, Y. J., D. Lehman, E. Garratty, R. Dickover, S. Plaeger-Marshall, and S. O'Rourke. 1993. The role of maternal autologous neutralizing antibody in prevention of maternal fetal HIV-1 transmission. J. Cell. Biochem. Suppl. 17E:95. |
| 6. | Bryson, Y. J., K. Luzuriaga, J. L. Sullivan, and D. W. Wara. 1992. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N. Engl. J. Med. 327:1246-1247[Medline]. |
| 7. | Cao, Y., P. Krogstad, B. T. Korber, R. A. Koup, M. Muldoon, C. Macken, J. L. Song, Z. Jin, J. Q. Zhao, S. Clapp, I. S. Chen, D. D. Ho, A. J. Ammanne, and the Ariel Project for the Prevention of HIV Transmission from Mother to Infant. 1997. Maternal HIV-1 viral load and vertical transmission of infection. Nat. Med. 3:549-552[CrossRef][Medline]. |
| 8. |
Connor, E. M.,
R. S. Sperling,
R. Gelber,
P. Kiselev,
G. Scott,
M. O'Sullivan,
R. VanDyke,
M. Bey,
W. Shearer,
R. L. Jacobson,
E. Jimenez,
E. O'Neill,
B. Bazin,
J. Delfraissy,
M. Culnane,
R. Coombs,
M. Elkins,
J. Moye,
P. Stratton, and J. Balsey.
1994.
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment.
N. Eng. J. Med.
331:1173-1180 |
| 9. | Contag, C. H., A. Ehrnst, J. Duda, A. B. Bohlin, S. Lindgren, G. H. Learn, and J. I. Mullins. 1997. Mother-to-infant transmission of human immunodeficiency virus type 1 involving five envelope sequence subtypes. J. Virol. 71:1292-1300[Abstract]. |
| 10. | Delwart, E. L., H. Pan, H. W. Sheppard, D. Wolpert, A. U. Neumann, B. Korber, and J. I. Mullins. 1997. Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J. Virol. 71:7498-7508[Abstract]. |
| 11. |
Delwart, E. L.,
H. W. Sheppard,
B. D. Walker,
J. Goudsmit, and J. I. Mullins.
1994.
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays.
J. Virol.
68:6672-6683 |
| 12. |
Delwart, E. L.,
E. G. Shpaer,
J. Louwagie,
F. E. McCutchan,
M. Grez,
H. Rubsamen-Waigmann, and J. I. Mullins.
1993.
Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes.
Science
262:1257-1261 |
| 13. | Dickover, R. E., M. Dillon, S. Gillette, A. Deveikis, M. Keller, S. Plaeger-Marshall, I. Chen, A. Diagne, S. E. R., and Y. J. Bryson. 1994. Rapid increases in HIV-1 load correlate with early disease progression and loss of CD4 cells in vertically infected infants. J. Infect. Dis. 170:1279-1284[Medline]. |
| 14. |
Dickover, R. E.,
E. M. Garratty,
S. A. Herman,
M. S. Sim,
S. Plaeger,
P. J. Boyer,
M. Keller,
A. Deveikis,
E. R. Stiehm, and Y. J. Bryson.
1996.
Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load.
JAMA
275:599-605 |
| 15. | Fontanet, A., and P. Piot. 1994. State of our knowledge: the epidemiology of HIV/AIDS. Health Transit Rev. 4(Suppl.):11-22. |
| 16. | Ganeshan, S., R. E. Dickover, B. T. Korber, Y. J. Bryson, and S. M. Wolinsky. 1997. Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease. J. Virol. 71:663-677[Abstract]. |
| 17. |
Garcia, P. M.,
L. A. Kalish,
J. Pitt,
H. Minkoff,
T. C. Quinn,
S. K. Burchett,
J. Kornegay,
B. Jackson,
J. Moye,
C. Hanson,
C. Zorrilla,
J. F. Lew, and the Women and Infants Transmission Study Group.
1999.
Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission.
N. Engl. J. Med.
341:394-402 |
| 18. | Hausner, A. M., J. V. Giorgi, and S. Plaeger-Marshall. 1993. A reproducible method to detect CD8 T cell mediated inhibition of HIV production from naturally infected CD4 cells. J. Immunol. Methods 157:181-187[CrossRef][Medline]. |
| 19. | Husson, R. N., Y. Lan, E. Kojima, D. Venzon, H. Mitsuya, and K. McIntosh. 1995. Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype. J. Pediatr. 126:865-871[CrossRef][Medline]. |
| 20. |
Kliks, S. C.,
D. W. Wara,
D. V. Landers, and J. A. Levy.
1994.
Features of HIV-1 that could influence maternal-child transmission.
JAMA
272:467-474 |
| 21. | Kuhn, L., R. W. Steketee, J. Weedon, E. J. Abrams, G. Lambert, M. Bamji, E. Schoenbaum, J. Farley, S. R. Nesheim, P. Palumbo, R. J. Simonds, D. M. Thea, and the Perinatal AIDS Collaborative Transmission Study. 1999. Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. J. Infect. Dis. 179:52-58[CrossRef][Medline]. |
| 22. | Lamers, S. L., J. W. Sleasman, J. X. She, K. A. Barrie, S. M. Pomeroy, D. J. Barrett, and M. M. Goodenow. 1994. Persistence of multiple maternal genotypes of human immunodeficiency virus type I in infants infected by vertical transmission. J. Clin. Investig. 93:380-390. |
| 23. |
Landesman, S. H.,
L. A. Kalish,
D. N. Burns,
H. Minkoff,
H. E. Fox,
C. Zorrilla,
P. Garcia,
M. G. Fowler,
L. Mofenson,
R. Tuomala, and the Women and Infants Transmission Study.
1996.
Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child.
N. Engl. J. Med.
334:1617-1623 |
| 24. | Lathey, J. L., J. Tsou, K. Brinker, K. Hsia, W. A. Meyer, 3rd, and S. A. Spector. 1999. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. J. Infect. Dis. 180:344-350[CrossRef][Medline]. |
| 25. | Narwa, R., P. Roques, C. Courpotin, F. Parnet-Mathieu, F. Boussin, A. Roane, D. Marce, G. Lasfargues, and D. Dormont. 1996. Characterization of human immunodeficiency virus type 1 p17 matrix protein motifs associated with mother-to-child transmission. J. Virol. 70:4474-4483[Abstract]. |
| 26. | Panther, L. A., L. Tucker, C. Xu, R. E. Tuomala, J. I. Mullins, and D. J. Anderson. 2000. Genital tract human immunodeficiency virus type 1 (HIV-1) shedding and inflammation and HIV-1 env diversity in perinatal HIV-1 transmission. J. Infect. Dis. 181:555-563[CrossRef][Medline]. |
| 27. | Philpott, S., H. Burger, T. Charbonneau, R. Grimson, S. H. Vermund, A. Visosky, S. Nachman, A. Kovacs, P. Tropper, H. Frey, and B. Weiser. 1999. CCR5 genotype and resistance to vertical transmission of HIV-1. J. Acquir. Immune Defic. Syndr. 21:189-193. |
| 28. | Plaeger, S., S. Bermudez, Y. Mikyas, N. Harawa, R. Dickover, D. Mark, M. Dillon, Y. J. Bryson, P. J. Boyer, and J. S. Sinsheimer. 1999. Decreased CD8 cell-mediated viral suppression and other immunologic characteristics of women who transmit human immunodeficiency virus to their infants. J. Infect. Dis. 179:1388-1394[CrossRef][Medline]. |
| 29. |
Poss, M.,
A. G. Rodrigo,
J. J. Gosink,
G. H. Learn,
D. de Vange Panteleeff,
H. L. Martin, Jr.,
J. Bwayo,
J. K. Kreiss, and J. Overbaugh.
1998.
Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1.
J. Virol.
72:8240-8251 |
| 30. |
Pulsinelli, G. A., and H. M. Temin.
1994.
High rate of mismatch extension during reverse transcription in a single round of retrovirus replication.
Proc. Natl. Acad. Sci. USA
91:9490-9494 |
| 31. | Quin, T. C. 1995. The epidemiology of the acquired immunodeficiency syndrome in the 1990s. Emerg. Med. Clin. N. Am. 13:1-25[Medline]. |
| 32. | Ratner, L., A. Fisher, L. L. Jagodzinski, H. Mitsuya, R. S. Liou, R. C. Gallo, and F. Wong-Staal. 1987. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res. Hum. Retrovir. 3:57-69[Medline]. |
| 33. | Saglio, S. D., J. T. Kurtzman, and A. B. Radner. 1996. HIV infection in women: an escalating health concern. Am. Fam. Physician 54:1541-1548[Medline], 1554-1556. |
| 34. | Shaffer, N., A. Roongpisuthipong, W. Siriwasin, T. Chotpitayasunondh, S. Chearskul, N. L. Young, B. Parekh, P. A. Mock, C. Bhadrakom, P. Chinayon, M. L. Kalish, S. K. Phillips, T. C. Granade, S. Subbarao, B. G. Weniger, T. D. Mastro, and Bangkok Collaborative Perinatal HIV Transmission Study Group. 1999. Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. J. Infect. Dis. 179:590-599[CrossRef][Medline]. |
| 35. |
Sperling, R. S.,
D. E. Shapiro,
R. W. Coombs,
J. A. Todd,
S. A. Herman,
G. D. McSherry,
M. J. O'Sullivan,
R. B. Van Dyke,
E. Jimenez,
C. Rouzioux,
P. M. Flynn,
J. L. Sullivan,
the Pediatric AIDS Clinical Trials Group, and the Protocol 076 Study Group.
1996.
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant.
N. Engl. J. Med.
335:1621-1629 |
| 36. | Stiehm, E. R., J. S. Lambert, L. M. Mofenson, J. Bethel, J. Whitehouse, R. Nugent, J. Moye, Jr., M. Glenn Fowler, B. J. Mathieson, P. Reichelderfer, G. J. Nemo, J. Korelitz, W. A. Meyer, 3rd, C. V. Sapan, E. Jimenez, J. Gandia, G. Scott, M. J. O'Sullivan, A. Kovacs, A. Stek, W. T. Shearer, and H. Hammill. 1999. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group Protocol 185. J. Infect. Dis. 179:567-575[CrossRef][Medline]. |
| 37. | Wain-Hobson, S. 1993. The fastest genome evolution ever described: HIV variation in situ. Curr. Opin. Genet. Dev. 3:878-883[CrossRef][Medline]. |
| 38. |
Wilson, C. C.,
R. C. Brown,
B. T. Korber,
B. M. Wilkes,
D. J. Ruhl,
D. Sakamoto,
K. Kunstman,
K. Luzuriaga,
I. C. Hanson,
S. M. Widmayer,
A. Wiznia,
S. Clapp,
A. J. Ammann,
R. A. Koup,
S. M. Wolinsky, and B. D. Walker.
1999.
Frequent detection of escape from cytotoxic T-lymphocyte recognition in perinatal human immunodeficiency virus (HIV) type 1 transmission: the Ariel Project for the Prevention of Transmission of HIV from Mother to Infant.
J. Virol.
73:3975-3985 |
| 39. | Wolinsky, S. M., B. T. Korber, A. U. Neumann, M. Daniels, K. J. Kunstman, A. J. Whetsell, M. R. Furtado, Y. Cao, D. D. Ho, and J. T. Safrit. 1996. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272:537-542[Abstract]. |
| 40. |
Wolinsky, S. M.,
C. M. Wike,
B. T. Korber,
C. Hutto,
W. P. Parks,
L. L. Rosenblum,
K. J. Kunstman,
M. R. Furtado, and J. L. Munoz.
1992.
Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants.
Science
255:1134-1137 |
| 41. |
Zhang, L. Q.,
P. MacKenzie,
A. Cleland,
E. C. Holmes,
A. J. Brown, and P. Simmonds.
1993.
Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection.
J. Virol.
67:3345-3356 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»